JP2017507142A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507142A5
JP2017507142A5 JP2016553284A JP2016553284A JP2017507142A5 JP 2017507142 A5 JP2017507142 A5 JP 2017507142A5 JP 2016553284 A JP2016553284 A JP 2016553284A JP 2016553284 A JP2016553284 A JP 2016553284A JP 2017507142 A5 JP2017507142 A5 JP 2017507142A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
fgf
cartilage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553284A
Other languages
English (en)
Japanese (ja)
Other versions
JP6431082B2 (ja
JP2017507142A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053631 external-priority patent/WO2015124731A1/en
Publication of JP2017507142A publication Critical patent/JP2017507142A/ja
Publication of JP2017507142A5 publication Critical patent/JP2017507142A5/ja
Application granted granted Critical
Publication of JP6431082B2 publication Critical patent/JP6431082B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553284A 2014-02-20 2015-02-20 Fgf−18化合物の投与計画 Active JP6431082B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600.8 2014-02-20
EP14000600 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (3)

Publication Number Publication Date
JP2017507142A JP2017507142A (ja) 2017-03-16
JP2017507142A5 true JP2017507142A5 (enExample) 2018-03-01
JP6431082B2 JP6431082B2 (ja) 2018-11-28

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Country Status (25)

Country Link
US (2) US9889179B2 (enExample)
EP (2) EP3107559B1 (enExample)
JP (2) JP6431082B2 (enExample)
KR (2) KR102410986B1 (enExample)
CN (2) CN106232622A (enExample)
AR (2) AR099510A1 (enExample)
AU (2) AU2015220777B2 (enExample)
BR (2) BR112016018696A2 (enExample)
CA (1) CA2938791A1 (enExample)
DK (2) DK3119417T3 (enExample)
ES (2) ES2688551T3 (enExample)
HR (2) HRP20181572T1 (enExample)
HU (1) HUE040350T2 (enExample)
IL (2) IL247083B (enExample)
LT (2) LT3107559T (enExample)
MX (2) MX2016010872A (enExample)
NZ (1) NZ723148A (enExample)
PL (2) PL3119417T3 (enExample)
PT (2) PT3107559T (enExample)
RS (2) RS57853B1 (enExample)
RU (2) RU2700582C2 (enExample)
SG (2) SG11201606502YA (enExample)
SI (2) SI3119417T1 (enExample)
WO (2) WO2015124727A1 (enExample)
ZA (2) ZA201605547B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3107559B1 (en) 2014-02-20 2018-07-11 Merck Patent GmbH Fgf-18 compound dosing regimen
BR112016018681B1 (pt) 2014-02-20 2021-01-05 Merck Patent Gmbh sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura
WO2016120387A1 (en) 2015-01-29 2016-08-04 Ares Trading S.A. Immunoassays for high positively charged proteins
DK3419625T3 (da) 2016-02-22 2021-07-12 Novartis Ag Fremgangsmåder til anvendelse af fxr-agonister
PL3688468T3 (pl) 2017-09-29 2022-07-18 Merck Patent Gmbh Biomarkery stanu zapalnego do przewidywania odpowiedzi na związek fgf-18
DK3687558T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
US20220184180A1 (en) * 2019-02-08 2022-06-16 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis
KR102920449B1 (ko) 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
ES2706848T3 (es) * 2004-07-06 2019-04-01 Zymogenetics Inc Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
CA2658511C (en) 2006-08-25 2019-02-19 Ares Trading S.A. Use of fgf-18 compound to treat cartilage disorders
ZA200900426B (en) * 2006-08-25 2010-04-28 Ares Trading Sa Treatment of cartilage disorders with FGF-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
EP2688890B1 (en) * 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
EP3107559B1 (en) 2014-02-20 2018-07-11 Merck Patent GmbH Fgf-18 compound dosing regimen
AU2015220781B2 (en) 2014-02-20 2018-05-24 Merck Patent Gmbh FGF-18 in graft transplantation and tissue engineering procedures
BR112016018681B1 (pt) 2014-02-20 2021-01-05 Merck Patent Gmbh sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura

Similar Documents

Publication Publication Date Title
JP2017507142A5 (enExample)
JP2017512194A5 (enExample)
JP2012193216A5 (enExample)
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
JP2015517488A5 (enExample)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
JP2015057451A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2013231087A5 (enExample)
JP2015038135A5 (enExample)
JP2016519128A5 (enExample)
RU2016137289A (ru) Схема применения соединения fgf-18
MX2018008021A (es) Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
JP2017503014A5 (enExample)
JP2016539125A5 (enExample)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2013541583A5 (enExample)
JP2016530291A5 (enExample)
JP2015522603A5 (enExample)
JP2017507145A5 (enExample)
JP2016512247A5 (enExample)
JP2016505050A5 (enExample)
JP2017061488A5 (enExample)